Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Imogen Milner

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Indian Journal of Ophthalmology|March 17, 2021
Comments: Pendleton's <i>Ideas, Concerns and Expectations</i> model for improving outcomes through eye donation counselingImogen Milner, Naveed Hussain, Princess Imoru, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 23, 2025
Monitoring Treatment-Associated Receptor Expression in Multiple Sclerosis Using a Newly Developed Panel for Spectral Flow CytometryKatharina Robichon, Jennifer Taylor, Imogen Milner, et al.
BMJ Neurology Open|March 8, 2021
Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trialAnne C La Flamme, David Abernethy, Dalice Sim, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Indian Journal of Ophthalmology|March 17, 2021
Comments: Pendleton's <i>Ideas, Concerns and Expectations</i> model for improving outcomes through eye donation counselingImogen Milner, Naveed Hussain, Princess Imoru, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 23, 2025
Monitoring Treatment-Associated Receptor Expression in Multiple Sclerosis Using a Newly Developed Panel for Spectral Flow CytometryKatharina Robichon, Jennifer Taylor, Imogen Milner, et al.
BMJ Neurology Open|March 8, 2021
Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trialAnne C La Flamme, David Abernethy, Dalice Sim, et al.
Pageof 1